COMMUNIQUÉS West-GlobeNewswire

ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

13/11/2017 - 13:00

Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969 ) in children and adults with Leber’s congenital amaurosis 10 (LCA 10). [...]

Spero Therapeutics Announces Underwriters’ Option Exercise

13/11/2017 - 13:00

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO ), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel [...]

Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union

13/11/2017 - 13:00

CARMIEL, Israel, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]

AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update

13/11/2017 - 12:48

Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer's symptoms in adults with Down syndrome Strong [...]

Jounce Therapeutics Reports Third Quarter 2017 Financial Results

13/11/2017 - 12:30

- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial guidance - - Company to [...]

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017

13/11/2017 - 12:30

Total Revenues for Third Quarter were $22.9 million, an 18% Increase Total revenues for first 9 months of 2017 were $67.1 million, a 26% Increase On Track to Achieve $100 Million in Total Revenues in 2017 Guiding to $ [...]

Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs

13/11/2017 - 12:00

Higher Rates of Myocardial Infarction (Heart Attack) and Revascularization Procedures in Patients with High Triglycerides Were Drivers of the Composite Outcome MACE Rate 35% Higher in Patients Who, Despite Statin [...]

Fennec Provides Business Update And Reports Third Quarter 2017 Results

13/11/2017 - 12:00

During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint (p=0.0033) indicating a significant reduction in cisplatin induced hearing loss without any [...]

Notice of Annual General Meeting

13/11/2017 - 11:37

Please see enclosed pdf.

Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation

13/11/2017 - 11:30

PLYMOUTH, Minn., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL ), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that Anthem, Inc. now [...]

CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

13/11/2017 - 11:00

ZUG, Switzerland and CAMBRIDGE, Mass. and TÜBINGEN, Germany, and BOSTON, Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a genome editing company focused on creating transformative gene-based [...]

Veritas and Cannevert Hires the Essèntium Group as Their Agent in Puerto Rico USA

13/11/2017 - 09:05

VANCOUVER, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces that the Company through its research arm, Cannevert [...]

NANOBIOTIX présente de nouveaux résultats cliniques et précliniques confirmant le potentiel de NBTXR3 en Immuno-Oncologie, lors du congrès annuel du SITC

13/11/2017 - 08:02

Nanobiotix présente de nouveaux résultats cliniques et précliniques confirmant le potentiel de NBTXR3 en Immuno-Oncologie, lors du congrès annuel du SITC NBTXR3 activé par la radiothérapie induit une réponse [...]

NANOBIOTIX presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting

13/11/2017 - 08:02

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting NBTXR3 activated by radiotherapy induces a significant adaptive immune [...]

Xbrane Biopharma releases interim report for the period July to September 2017

13/11/2017 - 08:01

Press release 2017-11-13 Xbrane Biopharma ABs interim report for the period July - September 2017 is now available on the Company's website, www.xbrane.com . July to September Revenue SEK -47 thousand (-) EBITDA SEK -8, [...]

Novartis highlights its differentiated late stage pipeline at the R&D update and investor event

13/11/2017 - 07:01

RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a robust data package, even in [...]

argenx to Present at Upcoming Investor Conferences

13/11/2017 - 07:01

November 13, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Voyager Therapeutics to Host R&D Day on November 16, 2017

13/11/2017 - 00:00

CAMBRIDGE, Mass., Nov. 12, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, [...]

Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection

11/11/2017 - 23:45

– Clinical Data from Renal Cell Carcinoma Cohorts Presented in Oral Session at SITC 32 nd Annual Meeting – – Adenosine Pathway Gene Expression Associated with Response to Therapy and Resistance to Prior Anti PD-(L)-1 – [...]